Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exscientia plc
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
December 05, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Third Quarter 2023
November 09, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
November 02, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Parker Moss to Join Exscientia as EVP, Corporate Development
October 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
October 16, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Details Pipeline Prioritisation Strategy
October 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
September 20, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Second Quarter and First Half of 2023
August 10, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
July 10, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for First Quarter 2023
May 24, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
May 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
March 16, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
March 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Expansion of its Precision Oncology Pipeline
March 14, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
March 07, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in March
February 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
February 02, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
December 06, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
November 28, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business and Financial Update for the Third Quarter 2022
November 15, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
November 14, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
November 08, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Expands Biologics Design Capability with Automated Laboratory
November 03, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.